Dermatology and Therapy最新文献

{"title":"Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review.","authors":"Anshu Jonnalagadda, Rhys L Richmond, Gaurav N Pathak, Amar D Desai, Ummuguslum Yildiz-Altay, Jeffrey R Gehlhausen, Matthew D Vesely","doi":"10.1007/s13555-026-01888-7","DOIUrl":"https://doi.org/10.1007/s13555-026-01888-7","url":null,"abstract":"<p><strong>Background: </strong>Discoid lupus erythematosus (DLE) is the most common chronic form of cutaneous lupus erythematosus and can lead to scarring, dyspigmentation, and permanent alopecia. The disease often causes visible disfigurement and has a substantial psychosocial impact. Although many patients respond to standard treatment, a subset continues to experience persistent or relapsing disease that remains difficult to control.</p><p><strong>Methods: </strong>A focused literature search was performed using PubMed, Google Scholar, Web of Science, and Scopus to identify English-language studies published from January 1990 through October 2025. Search terms included \"discoid lupus erythematosus,\" \"cutaneous lupus erythematosus,\" \"chronic cutaneous lupus,\" \"pathogenesis,\" \"therapy,\" \"antimalarial,\" \"immunosuppressant,\" \"biologic therapy,\" \"JAK inhibitor,\" \"small molecule therapy,\" and \"targeted therapy.\" Recent clinical trials, consensus guidelines, and review articles were prioritized. Reference lists of key publications were manually screened to capture additional relevant studies.</p><p><strong>Results: </strong>Current first-line topical pharmacotherapeutic treatment options of DLE include photoprotection, topical corticosteroids, and calcineurin inhibitors for localized disease, and antimalarial therapy as a first-line systemic treatment. For refractory disease, systemic immunosuppressants remain common second-line options. Emerging therapies targeting interferon and cytokine signaling pathways, including anifrolumab, belimumab, and tyrosine kinase (TYK2) inhibitors such as deucravacitinib and the plasmacytoid dendritic cell modulators litifilimab and daxdilimab have shown early promise in improving cutaneous disease activity in patients with refractory DLE. Procedural modalities such as laser therapy are being studied as adjuncts for scarring and dyspigmentation.</p><p><strong>Conclusions: </strong>Ongoing advances in understanding the immune mechanisms underlying DLE are shaping a transition from broad immunosuppression toward more targeted treatment strategies. Integrating newer biologic and small-molecule therapies with conventional management may offer improved control and better long-term outcomes for patients with chronic disease.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.","authors":"Shirley Dehn, Daniel Cooper, Christian Weyer, Beatrice Ferguson, Swetha Srinivasan, Etienne Saint-Cyr Proulx, Robert Bissonnette","doi":"10.1007/s13555-026-01883-y","DOIUrl":"https://doi.org/10.1007/s13555-026-01883-y","url":null,"abstract":"<p><strong>Introduction: </strong>Mas-related G protein-coupled receptor X2 (MRGPRX2) levels are elevated in patients with atopic dermatitis (AD). EP262, a small-molecule MRGPRX2 receptor antagonist, significantly diminished AD development in humanized mouse models of AD. In the EASE study, the safety, tolerability, and pharmacodynamics of EP262 were compared with placebo in patients with AD.</p><p><strong>Methods: </strong>Patients aged 18-80 years with AD, 3%-20% affected body surface area, and validated Investigator's Global Assessment for AD (vIGA-AD) score ≥ 3 were randomized 2:1 to receive 150 mg EP262 or placebo once daily for 6 weeks. The primary endpoint was safety and tolerability. The secondary endpoint was change from baseline to Week 6 in gene expression signature and skin histology. Exploratory efficacy endpoints included Eczema Area and Severity Index (EASI), vIGA-AD, and Peak Pruritus Numerical Rating Scale (PP-NRS).</p><p><strong>Results: </strong>Of 32 randomized patients (median [range] age, 41.0 [18-70] years), treatment-emergent adverse events (TEAEs) were reported in 19.0% of patients who received EP262 and 63.6% who received placebo, with none considered treatment-related. No grade ≥ 3 or serious TEAEs were observed, and no TEAEs led to dose interruptions or treatment discontinuations. No genes were differentially expressed between baseline lesional or nonlesional samples and Week 6 lesional samples. Differences in epidermal thickness were not meaningful between groups following treatment. No improvement was observed at Week 6 between EP262 and placebo in EASI (mean percentage change from baseline, - 14.9% vs - 40.7%), vIGA-AD (patients scoring 0/1 with  ≥ 2-point improvement from baseline, 21.1% vs 27.3%), or PP-NRS scores (mean percentage change from baseline, - 26.7% vs - 25.1%).</p><p><strong>Conclusions: </strong>EP262 was well tolerated in patients with AD. No meaningful differences were observed in gene expression, skin thickness, or efficacy measures in patients who received EP262 versus placebo.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov identifier, NCT06144424 (registered on November 16, 2023).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.","authors":"April W Armstrong, Ahmed Ameen, Silvia Ferrucci, José-Juan Pereyra-Rodríguez, Michael J Cork, Cory Rubin, Abel Jarell, Alessandra Narcisi, Pierre-Andre Becherel, Jennifer Beecker, Teodora Festini, Ida Vittrup, Frank Vinther, Diamant Thaçi","doi":"10.1007/s13555-026-01869-w","DOIUrl":"https://doi.org/10.1007/s13555-026-01869-w","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic, inflammatory skin condition in which interleukin (IL)-13 is a key driver. Tralokinumab, an IL-13-targeting monoclonal antibody, has demonstrated efficacy and a favorable safety profile in patients with moderate-to-severe AD in phase 3 trials. However, data on long-term effectiveness and safety in routine clinical practice remain limited. This study aimed to assess changes in clinical signs and symptoms of AD and evaluate safety in patients treated with tralokinumab in a real-world setting.</p><p><strong>Methods: </strong>TRACE is an international, non-interventional, prospective study of adults with AD prescribed tralokinumab and followed for up to 12 months of treatment. The primary outcome was investigator-assessed AD severity (Investigator's Global Assessment [IGA], Eczema Activity and Severity Index [EASI], and/or SCORing AD [SCORAD]). Patient-reported outcomes (PROs) were collected if part of routine practice. Safety was also assessed.</p><p><strong>Results: </strong>A total of 824 patients (mean age 44.1 years; 24.9% with prior biologic therapy) were included. At baseline, 414 (50.3%) patients had moderate AD (IGA 3), 281 (34.1%) had severe AD (IGA 4), mean EASI was 20.1, and mean SCORAD was 47.1. Early improvements in AD clinical signs and symptoms were sustained over 12 months of treatment with tralokinumab, with the percentage of composite responders (IGA 0/1, EASI-75, or SCORAD < 10) increasing from 5.3% at baseline to 79.1% at month 12. Rapid and sustained improvements in PROs were also reported throughout the study. AEs were reported by 232 (28.1%) patients, with the majority being non-serious and mild or moderate in severity. Conjunctivitis was reported in 4.4% of patients.</p><p><strong>Conclusions: </strong>TRACE is the largest real-world study of tralokinumab to date. Treatment with tralokinumab over 12 months substantially improved signs and symptoms of AD as well as PROs across all outcome measures, providing evidence supporting the rapid and long-term effectiveness of tralokinumab. No new safety signals were identified.</p><p><strong>Trial registration: </strong>EU PAS register-EUPAS44659.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.","authors":"Thierry Passeron, Richard Ta, Véronique Hospital, Keith A Betts, Maryaline Catillon, Calvin Plays, Denis Jullien","doi":"10.1007/s13555-026-01887-8","DOIUrl":"https://doi.org/10.1007/s13555-026-01887-8","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world evidence investigating treatment patterns and associated economic outcomes in patients with psoriasis (PsO) are lacking. This study evaluated treatment patterns, healthcare resource utilisation (HCRU), and costs in biologic-naïve patients with moderate-to-severe PsO initiating biologics in France.</p><p><strong>Methods: </strong>Biologic-naïve adults with moderate-to-severe PsO initiating an anti-tumour necrosis factor (TNFα) or anti-interleukin (IL) biologic were identified from the Système National des Données de Santé. Switching and dose escalation rates, calculated using Kaplan-Meier analyses, were assessed over 42 months of follow-up. HCRU and costs were assessed during the 12 months following initiation. Comparisons between switchers/non-switchers and dose escalators/non-dose escalators were conducted using Wilcoxon rank sum, chi-square, and Fisher exact tests.</p><p><strong>Results: </strong>Overall, 20,995 biologic-naïve adult patients initiating a biologic were included in the analysis. At 42 months, switch rates and dose escalation rates were lowest for patients initiating anti-IL-23 agents and highest for anti-TNFα agents. Specifically, the lowest rate of switching (15.0%) and dose escalation (9.0%) were observed for patients treated with the anti-IL-23 agent risankizumab. The mean number of total healthcare visits at 12 months was significantly (p < 0.001) higher for treatment switchers versus non-switchers (48.8 vs 39.0) and dose escalators versus non-dose escalators (47.4 vs 39.9). Furthermore, switchers had significantly (p < 0.001) higher mean medical (€3435 vs €2578), inpatient (€1126 vs €826), outpatient (€1751 vs €1331), and pharmacy (€13,105 vs €10,589) costs versus non-switchers. Similar trends were observed for dose escalators versus non-dose escalators (€3453 vs €2638; €965 vs €870; €1682 vs €1371; and €13,736 vs €10,683, respectively, p < 0.001).</p><p><strong>Conclusion: </strong>Anti-IL-23 agents demonstrated the lowest rates of switching and dose escalation over 42 months, whilst anti-TNFα agents had the highest rates. More specifically, the lowest rates were observed for patients treated with risankizumab. Overall, higher rates of switching or dose escalation corresponded with higher HCRU and costs.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Previous Aesthetic Procedures among Men: A Cross-Sectional Online Survey.","authors":"Andreza Cunha Moreira, Ana Claudia Carbone, Antony de Paula Barbosa, Murilo Fanchiotti Cerri, Anna Raphaella Autran Colaco, Gilberto Melo, Giancarlo De la Torre Canales","doi":"10.1007/s13555-026-01889-6","DOIUrl":"https://doi.org/10.1007/s13555-026-01889-6","url":null,"abstract":"<p><strong>Introduction: </strong>The number of men undergoing aesthetic procedures has increased substantially worldwide, highlighting the need to understand the characteristics of those who undergo them. However, evidence focusing on male populations remains limited. This study aimed to describe the sociodemographic characteristics and FACE-Q scale patient-reported outcomes of men with and without previous aesthetic procedures, and to explore which characteristics were associated with having undergone them.</p><p><strong>Methods: </strong>This cross-sectional online survey included 231 men aged 18-65 years. Participants were allocated into two groups according to previous experience with aesthetic procedures: yes to aesthetic procedures (YAP; n = 93) and no to aesthetic procedures (NAP; n = 138). Sociodemographic variables and six independently functioning FACE-Q scales were collected: aging appraisal, appearance-related psychosocial distress, satisfaction with facial appearance, psychological function, social function, and satisfaction with lower face and jawline. Univariate between-group comparisons and exploratory multivariate analyses were performed.</p><p><strong>Results: </strong>Participants in the YAP group were more frequently from Brazil, aged ≥ 31 years, and in the higher-income group (p < 0.05). They reported lower Aging Appraisal scores, (trimmed mean difference -15.8; 95% CI -21.6 to -9.9), greater appearance-related psychosocial distress (+13.1; 95% CI 6.4-19.7), and lower satisfaction with facial appearance (- 8.6), psychological function (-8.6), and satisfaction with the lower face and jawline (-11.4). Multivariate analysis showed substantial overlap between groups (R²Y = 0.292; Q² = 0.256). In the exploratory logistic regression, Brazilian participants (OR 0.29; 95% CI 0.14-0.57), age ≥ 31 years (OR 2.35; 95% CI 1.08-5.13), and higher income (OR 2.90; 95% CI 1.27-6.61) were associated with previous aesthetic procedures, whereas no FACE-Q scale was independently associated with the outcome.</p><p><strong>Conclusions: </strong>Men undergoing previous aesthetic procedures did not demonstrate a clearly psychosocial profile compared with the general male population. However, age, country, and income, but not any FACE-Q, were independently associated with undergoing these procedures.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.","authors":"Ruohan Zhao, Huilin Xu, Yirui Zhu, Huailong Chang, Bin Liu, Zhongwang Liu","doi":"10.1007/s13555-026-01892-x","DOIUrl":"https://doi.org/10.1007/s13555-026-01892-x","url":null,"abstract":"<p><p>The gut-brain-skin axis is a proposed integrative framework describing interactions among the gastrointestinal tract, skin, and nervous system through neural, endocrine, immune, and microbial processes. Accumulating evidence has redefined the skin as a sophisticated neuro-immune-endocrine organ rather than a passive barrier, providing the fundamental mechanistic basis for the burgeoning interdisciplinary field of neurocosmetics. However, most existing reviews have focused on the unidirectional regulation from gut to skin and from brain to skin, lacking systematic analysis of the reverse signaling from skin to nervous system and its potential for cosmetic transformation. This article addresses this gap by providing a comprehensive, mechanism-oriented integrative discussion of the gut-brain-skin axis, with a focus on the ascending skin-to-central signal pathways and their significance for neurocosmetics. This review first establishes the gut-brain axis as the core framework for barrier organ-central nervous system crosstalk, then systematically delineates the key molecular and cellular mechanisms underlying the skin-brain axis-the central pillar of neurocosmetics. This article further identifies conserved regulatory hubs and shared pathological mechanisms that underlie the comorbidity of atopic dermatitis, depression, and irritable bowel syndrome. Building on this integrated framework, this review evaluates several mechanistically grounded neurocosmetic development strategies, identifies pressing translational challenges, and proposes priority directions for future research. In summary, this article provides an evidence-based framework for understanding how the gut-brain-skin axis underpins the scientific basis of neurocosmetics and proposes a translational skincare framework that integrates overall homeostasis, stress protection, and emotional health.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the Kingdom of Saudi Arabia.","authors":"Mohammed Abdulaziz F Al Ajlan, Khalidah A Alenzi, Mohammed A Al-Haddab, Ibtisam AlHarbi, Abdulrahman Alturaiki, Mohammad Saeed Arsalan, Ayman Behiry, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa","doi":"10.1007/s13555-026-01873-0","DOIUrl":"https://doi.org/10.1007/s13555-026-01873-0","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with a prevalence of approximately 2% in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study described dermatologist perceptions and experiences treating AA in the Kingdom of Saudi Arabia (KSA) while new treatments were introduced, and examined patient disease burden and unmet treatment need.</p><p><strong>Methods: </strong>Data were analyzed from the Adelphi Real World AA Disease Specific Programme™, conducted September 2022-March 2023. Dermatologists rated their agreement with statements on diagnosing/managing AA and provided clinical and treatment information for four patients (mild/moderate AA: one each; severe/very severe AA: two). A subset of these patients completed the SKINDEX-16, Hospital Anxiety and Depression Scale (HADS), and the Work Productivity and Activity Impairment-AA (WPAI-AA) questionnaires. Analyses were stratified by percent scalp hair loss (SHL).</p><p><strong>Results: </strong>A total of 50 dermatologists and 185 patients were included. Most dermatologists reported severe AA was difficult to treat owing to lack of effective therapies. A median of 51.5% SHL was reported as typical of severe AA. Impact of AA on patient QoL was the most frequently reported factor informing disease severity. Overall, 52.4% of patients had severe or very severe AA (as assessed by their physician). Approximately one-third of patients had abnormal anxiety and depression scores as measured by HADS. Patients with ≤ 20% SHL generally had lower mean Skindex-16 scores (impact of AA on QoL). Patients with ≥ 50% SHL reported greater work and activity impacts on the WPAI-AA. Most patients were receiving their first AA treatment, with the most common treatments differing by SHL category. Healthcare resource utilization and costs were greater among patients with ≥ 50% SHL.</p><p><strong>Conclusions: </strong>In the KSA, the burden of AA extends beyond SHL to include both mental health and economic burdens, highlighting the need for effective treatments.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates.","authors":"Fatima Albreiki, Ayman Ahmed Essa Al Naeem, Muna Mohamed Al Safi, Ahmed Ameen, Pervaz Ahmad Mohammad, Mostafa Zayed, Haytham Mohamed Ahmed, Diala Hamza, Zeina Azrak, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa","doi":"10.1007/s13555-026-01874-z","DOIUrl":"https://doi.org/10.1007/s13555-026-01874-z","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with approximately 2% prevalence in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study evaluated dermatologist perceptions and experiences treating AA in the United Arab Emirates (UAE) as new targeted treatments became available, as well as patient disease burden and unmet treatment needs.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World AA Disease Specific Programme™ (September 2022-March 2023). Dermatologists rated statements on diagnosing and managing AA by agreeing or disagreeing and provided clinical and treatment information on one patient each with mild, moderate, and severe/very severe AA. Some of these patients completed questionnaires (Skindex-16, Hospital Anxiety and Depression Scale, and Work Productivity and Activity Impairment-AA [WPAI-AA]). Results stratification included by percent scalp hair loss (SHL).</p><p><strong>Results: </strong>Analyses included 53 dermatologists and 144 patients. Most dermatologists reported severe AA management was difficult because of lack of effective treatments. A median SHL of 61.0% was reported as typical of severe AA. The most frequently reported factor informing disease severity was impact of AA on QoL. Overall, 32.6% of patients had physician-assessed severe/very severe AA. Anxiety and depression rates were consistent across SHL categories. Patients with ≥ 21% SHL reported significantly higher impact of AA on QoL (mean Skindex-16 scores). Patients with ≥ 50% SHL reported higher presenteeism on the WPAI-AA. Almost all patients were currently receiving their first AA treatment; patients with ≥ 50% SHL received different treatments than those with < 50% SHL. Healthcare resource utilization and costs were lower among patients with < 50% SHL.</p><p><strong>Conclusions: </strong>In the UAE, impacts on patient QoL and the economic burden associated with AA are important factors to consider and may aid dermatologists in setting treatment goals and selecting therapies as newer targeted therapies emerge.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Retinol, Alone or Combined with Medical Photoprotection, in Patients with Actinic Keratosis: A Randomized, Open-Label, Prospective, Multicentric Study.","authors":"Marco Ardigò, Martina Burlando, Elena Campione, Gianluca Nazzaro, Giulio Foggi, Francesca Colombo, Stefano Alfano, Massimo Milani, Angelo V Marzano","doi":"10.1007/s13555-026-01881-0","DOIUrl":"https://doi.org/10.1007/s13555-026-01881-0","url":null,"abstract":"<p><strong>Introduction: </strong>Actinic keratosis (AK) is a chronic ultraviolet-induced condition with potential progression to squamous cell carcinoma. This study assessed the efficacy and tolerability of oral retinol, alone or combined with broad-spectrum medical photoprotection containing piroxicam, in patients with mild-to-moderate AK.</p><p><strong>Methods: </strong>In this multicenter, prospective, randomized, open-label study, 117 patients with up to six AK lesions were assigned to oral retinol 50,000 international units (IU)/day (group A), oral retinol plus medical photoprotection (group B), or standard photoprotection recommendations (group C). Treatment lasted 6 months, followed by 3 months of follow-up. Assessments were performed at baseline and at months 3, 6, and 9. The primary endpoint was change in Actinic Keratosis Area and Severity Index (AKASI). Secondary outcomes included global clinical efficacy, lesion clearance, tolerability, and exploratory line-field confocal optical coherence tomography findings.</p><p><strong>Results: </strong>All 117 patients were included in the intention-to-treat analysis, and 99 in the per-protocol analysis. AKASI scores decreased significantly in group A at month 6 by - 19.3% (mean difference (MD) 0.61, 95% confidence interval (CI) 0.11-1.11; p < 0.05) and at month 9 by - 22.5% (MD 0.71, 95% CI 0.18-1.25; p < 0.01). In group B, significant reductions were observed at all time points (T3: - 24.1%; MD 0.90, 95% CI 0.42-1.39; p < 0.0001; T6: - 34.9%; MD 1.31, 95% CI 0.86-1.76; p < 0.0001; T9: - 38.8%; MD 1.45, 95% CI 0.95-1.95; p < 0.0001). No significant changes occurred in group C. Reductions were earlier and greater with the combined strategy. Global clinical efficacy was rated good or very good in 69% of patients in group A and 88% in group B, while lesion clearance rates were 56% and 82%, respectively. Tolerability was generally good, and no treatment-related adverse events were formally recorded. In the imaging substudy, significant reductions in epidermal and stratum corneum thickness occurred only in group B.</p><p><strong>Conclusions: </strong>Oral retinol combined with medical photoprotection was associated with earlier and greater improvements than oral retinol alone or standard photoprotection recommendations. These findings support further controlled studies to confirm efficacy and clarify the contribution of each intervention.</p><p><strong>Trial registration: </strong>Trial registration number ISRCTN42565762, retrospectively registered on 18 May 2026.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of \"Ozempic Face\".","authors":"Saroja Rao, Isabella Midura, Kathyana P Santiago Mangual, Leon I Igel, Katherine H Saunders, Jocelyn Carter, Jenny E Murase, Arianne Shadi Kourosh","doi":"10.1007/s13555-026-01882-z","DOIUrl":"https://doi.org/10.1007/s13555-026-01882-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;With the surge in use of glucagon-like peptide 1-receptor agonists (GLP-1RAs) for weight management, \"Ozempic Face,\" one of the dermatologic effects describing facial hollowing, sinking cheeks, and skin laxity, has drawn public attention. While substantial media discourse has surrounded certain dermatologic effects, patient-reported data is needed to more accurately characterize them. This study identifies patient-reported changes in skin, hair, and nails associated with weight management treatment with GLP-1RAs, including the frequency of dermatologic effects relative to weight loss.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Our study was conducted through an IRB-approved, voluntary, anonymous survey developed via collaboration between obesity medicine physicians and dermatologists. The survey was then distributed to patients of a virtual cardio-kidney-metabolic treatment program. Responses (n = 1226) were sorted by the percent body weight lost and categorized by medication regimen (glucagon-like peptide 1-receptor agonists; GLP-1RA, nonGLP-1RA, or combination therapy). Patients reported dermatologic and overall physical changes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Dermatologic effects were reported more frequently with greater weight loss. Of respondents reporting greater than 20% body weight loss, (n = 325) 233 (72%; 95% CI 67-76) reported skin sagging, (n = 325) 170 (52%; 95% CI 47-58) reported hair loss, (n = 325) 163 (50%; 95% CI 45-55) reported decreased facial volume, and (n = 325) 107 (33%; 95% CI 28-38) reported reduced strength. Of respondents reporting 10-20% weight loss, (n = 395) 172 (44%; 95% CI 39-49) reported skin sagging, (n = 395) 119 (30%; 95% CI 26-35) reported hair loss, (n = 395) 147 (37%; 95% CI 33-42) reported decreased facial volume, and (n = 395) 76 (19%; 95% CI 16-23%) reported reduced strength. In comparison, of respondents reporting less than 10% weight loss, only (n = 380) 57 (15%; 95% CI 12-19) reported skin sagging, (n = 380) 65 (17%; 95% CI 13-21) reported hair loss, (n = 380) 48 (13%; 95% CI 10-16) reported decreased facial volume, and (n = 380) 35 (9%; 95% CI 7-13) reported reduced strength. The frequency of adverse patient-reported outcomes increased significantly with increasing percentage of body weight loss. Cochran-Armitage trend testing identified significant positive trends across the &lt; 10%, 10-20%, and &gt; 20% body weight loss categories for skin sagging (Z = 15.22), hair loss (Z = 9.91), decreased facial volume (Z = 10.70), and reduced strength (Z = 7.85), with P values of &lt; 0.001. Among survey respondents on at least one GLP-1RA medication therapy, improvement was reported in certain preexisting inflammatory and hormonally driven skin conditions, including hidradenitis suppurativa (n = 15), 13 (87%; 95% CI 60-98); acanthosis nigricans (n = 12), 9 (75%; 95% CI 43-93); psoriasis (n = 47), 22 (47%; 95% CI 32-62); acne (n = 41), 17 (41%; 95% CI 27-57); eczema (n = 64), 17 (27%; 95% CI 17","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}